Cargando…

Declined ELABELA plasma levels in hypertension patients with atrial fibrillation: a case control study

BACKGROUND: Atrial fibrillation (AF) is a common arrhythmia in patients with hypertension. ELABELA, which has cardioprotective effects, is decreased in the plasma of patients with hypertension and might be associated with AF in the hypertensive population. This study aims to measure the ELABELA plas...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Zheng, Zhao, Lei, Zhang, Ye-ping, Zhong, Jiu-chang, Yang, Xin-chun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8359615/
https://www.ncbi.nlm.nih.gov/pubmed/34384364
http://dx.doi.org/10.1186/s12872-021-02197-x
_version_ 1783737584535470080
author Ma, Zheng
Zhao, Lei
Zhang, Ye-ping
Zhong, Jiu-chang
Yang, Xin-chun
author_facet Ma, Zheng
Zhao, Lei
Zhang, Ye-ping
Zhong, Jiu-chang
Yang, Xin-chun
author_sort Ma, Zheng
collection PubMed
description BACKGROUND: Atrial fibrillation (AF) is a common arrhythmia in patients with hypertension. ELABELA, which has cardioprotective effects, is decreased in the plasma of patients with hypertension and might be associated with AF in the hypertensive population. This study aims to measure the ELABELA plasma levels in hypertension patients with and without AF and to analyse the related factors. METHODS: A total of 162 hypertension patients with or without AF were recruited for our monocentric observational study. Subjects were excluded if they had a history of valvular heart disease, rheumatic heart disease, cardiomyopathy, thyroid diseases, or heart failure. The patients’ histories were recorded, and laboratory examinations were conducted. Plasma ELABELA was detected by immunoassay. Echocardiographs were performed, and parameters were collected by two experienced doctors. Binary logistic regression analysis was used to identify the association between ELABELA plasma level and AF in patients with hypertension. RESULTS: Plasma ELABELA levels were lower in hypertension patients with AF than in those without AF (2.0 [1.5, 2.8] vs. 4.0 [3.4, 5.0] ng/ml, P < 0.001). ELABELA levels were correlated with age, heart rate, BNP levels and left atrial dimension. In addition to the left atrial dimension, ELABELA plasma levels were associated with AF in patients with hypertension (OR 0.081, 95% CI 0.029–0.224, P < 0.001). ELABELA levels were further decreased in the persistent AF subgroup compared with the paroxysmal AF subgroup (1.8 [1.4, 2.5] vs. 2.2 [1.8, 3.0] ng/ml, P = 0.012) and correlated with HR, BNP and ESR levels. CONCLUSIONS: ELALABELA levels were decreased in hypertension patients with AF and further lowered in the persistent AF subgroup. Decreased ELABELA plasma levels were associated with AF in hypertension patients and may be an underlying risk factor. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12872-021-02197-x.
format Online
Article
Text
id pubmed-8359615
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-83596152021-08-16 Declined ELABELA plasma levels in hypertension patients with atrial fibrillation: a case control study Ma, Zheng Zhao, Lei Zhang, Ye-ping Zhong, Jiu-chang Yang, Xin-chun BMC Cardiovasc Disord Research Article BACKGROUND: Atrial fibrillation (AF) is a common arrhythmia in patients with hypertension. ELABELA, which has cardioprotective effects, is decreased in the plasma of patients with hypertension and might be associated with AF in the hypertensive population. This study aims to measure the ELABELA plasma levels in hypertension patients with and without AF and to analyse the related factors. METHODS: A total of 162 hypertension patients with or without AF were recruited for our monocentric observational study. Subjects were excluded if they had a history of valvular heart disease, rheumatic heart disease, cardiomyopathy, thyroid diseases, or heart failure. The patients’ histories were recorded, and laboratory examinations were conducted. Plasma ELABELA was detected by immunoassay. Echocardiographs were performed, and parameters were collected by two experienced doctors. Binary logistic regression analysis was used to identify the association between ELABELA plasma level and AF in patients with hypertension. RESULTS: Plasma ELABELA levels were lower in hypertension patients with AF than in those without AF (2.0 [1.5, 2.8] vs. 4.0 [3.4, 5.0] ng/ml, P < 0.001). ELABELA levels were correlated with age, heart rate, BNP levels and left atrial dimension. In addition to the left atrial dimension, ELABELA plasma levels were associated with AF in patients with hypertension (OR 0.081, 95% CI 0.029–0.224, P < 0.001). ELABELA levels were further decreased in the persistent AF subgroup compared with the paroxysmal AF subgroup (1.8 [1.4, 2.5] vs. 2.2 [1.8, 3.0] ng/ml, P = 0.012) and correlated with HR, BNP and ESR levels. CONCLUSIONS: ELALABELA levels were decreased in hypertension patients with AF and further lowered in the persistent AF subgroup. Decreased ELABELA plasma levels were associated with AF in hypertension patients and may be an underlying risk factor. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12872-021-02197-x. BioMed Central 2021-08-12 /pmc/articles/PMC8359615/ /pubmed/34384364 http://dx.doi.org/10.1186/s12872-021-02197-x Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Ma, Zheng
Zhao, Lei
Zhang, Ye-ping
Zhong, Jiu-chang
Yang, Xin-chun
Declined ELABELA plasma levels in hypertension patients with atrial fibrillation: a case control study
title Declined ELABELA plasma levels in hypertension patients with atrial fibrillation: a case control study
title_full Declined ELABELA plasma levels in hypertension patients with atrial fibrillation: a case control study
title_fullStr Declined ELABELA plasma levels in hypertension patients with atrial fibrillation: a case control study
title_full_unstemmed Declined ELABELA plasma levels in hypertension patients with atrial fibrillation: a case control study
title_short Declined ELABELA plasma levels in hypertension patients with atrial fibrillation: a case control study
title_sort declined elabela plasma levels in hypertension patients with atrial fibrillation: a case control study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8359615/
https://www.ncbi.nlm.nih.gov/pubmed/34384364
http://dx.doi.org/10.1186/s12872-021-02197-x
work_keys_str_mv AT mazheng declinedelabelaplasmalevelsinhypertensionpatientswithatrialfibrillationacasecontrolstudy
AT zhaolei declinedelabelaplasmalevelsinhypertensionpatientswithatrialfibrillationacasecontrolstudy
AT zhangyeping declinedelabelaplasmalevelsinhypertensionpatientswithatrialfibrillationacasecontrolstudy
AT zhongjiuchang declinedelabelaplasmalevelsinhypertensionpatientswithatrialfibrillationacasecontrolstudy
AT yangxinchun declinedelabelaplasmalevelsinhypertensionpatientswithatrialfibrillationacasecontrolstudy